(Q37385371)

20 August 2017

1 reference

title

Bendamustine in the treatment of chronic lymphocytic leukemia (English)

1 reference

20 August 2017

0 references

1 reference

1 reference

Wolfgang Knauf

1

1 reference

20 August 2017

publication date

1 February 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

165-174

1 reference

20 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Alkylating DNA damage stimulates a regulated form of necrotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

In vitro studies with bendamustine: enhanced activity in combination with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.2.165

21 January 2018

Identifiers

DOI

10.1586/14737140.9.2.165

1 reference

20 August 2017

1 reference